Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Microarrays & Multiplexing › NanoString, Riken Genesis to Commercialize Diagnostic Assays in Japan

NanoString, Riken Genesis to Commercialize Diagnostic Assays in Japan

Jan 04, 2018
|
staff reporter

NEW YORK (GenomeWeb) – NanoString Technologies and Sysmex subsidiary Riken Genesis said today that they have entered into a partnership to bring nCounter-based diagnostic assays to the Japanese market. 

Under the agreement, NanoString and Riken will collaborate to commercialize, register, and gain reimbursement for companion diagnostic tests, including a lymphoma subtyping test that  will be marketed as the nCounter Dx LymphMark assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

What's Popular?

In Molecular Diagnostics

  1. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

  2. LumiraDx to Go Public on Nasdaq Through SPAC

  3. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

  4. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

  5. NIH RADx Program Awards $29.3M to Increase SARS-CoV-2 Testing Capacity

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.